{"product_id":"tesamorelin-10mg-3ml-research-peptide-uk","title":"Tesamorelin 10mg 3ml Research Peptide UK","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFor research use only. Not for human consumption.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTesamorelin (TH9507) — 10mg | Pre-Mixed 3ml Vial | ≥99% Purity | COA Verified | UK Dispatch\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin is a synthetic 44-amino acid analogue of endogenous human Growth Hormone-Releasing Hormone (GHRH 1–44), distinguished by the addition of a \u003cstrong\u003etrans-3-hexenoic acid group\u003c\/strong\u003e at the N-terminus. This structural modification significantly increases resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), extending the peptide's stability and half-life in biological research environments compared to native GHRH. Tesamorelin is the only FDA-approved compound in the GHRH analogue class, receiving approval in 2010 under the brand name Egrifta for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy — providing one of the most robust clinical evidence bases of any research peptide in the GH\/IGF-1 axis category.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThis listing features a \u003cstrong\u003epre-mixed, ready-to-use 3ml vial\u003c\/strong\u003e containing \u003cstrong\u003e10mg of research-grade Tesamorelin\u003c\/strong\u003e, providing consistent laboratory-ready concentration for precise experimental workflows.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism of Action in Research\u003c\/strong\u003e Tesamorelin acts as a selective \u003cstrong\u003eGHRH receptor (GHRHR) agonist\u003c\/strong\u003e, binding to pituitary GHRH receptors to stimulate endogenous GH synthesis and pulsatile secretion via Gs protein-coupled cAMP\/PKA signalling cascades. In research models this produces downstream:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eStimulation of the GH\/IGF-1 axis with subsequent IGF-1 elevation\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eEnhanced lipolysis in visceral adipose tissue through GH-mediated fat mobilisation pathways\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003ePreservation of pulsatile GH secretion patterns — unlike continuous GH administration, GHRH analogues maintain physiological GH pulse architecture\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eModulation of endocrine feedback loops including somatostatin-mediated negative regulation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eKey Research Areas\u003c\/strong\u003e Tesamorelin is one of the most clinically validated peptides in the GHRH class, with significant preclinical and clinical data across multiple research domains:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eVisceral adipose tissue \u0026amp; lipodystrophy\u003c\/strong\u003e — Phase II and III clinical trial data demonstrate statistically significant reductions in visceral adipose tissue volume; the foundational research area and basis of FDA approval in HIV-associated lipodystrophy\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eGH\/IGF-1 axis modulation\u003c\/strong\u003e — widely used in endocrinology research to study GHRH receptor signalling kinetics, pituitary GH secretion dynamics, downstream IGF-1 regulation, and somatotropic axis feedback mechanisms\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCognitive function research\u003c\/strong\u003e — multiple clinical studies have investigated tesamorelin's effects on cognitive performance in older adults; a double-blind RCT demonstrated improvements in executive function and verbal memory in cognitively normal older individuals, linked to IGF-1 elevation and possible neuroprotective mechanisms\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMetabolic \u0026amp; body composition research\u003c\/strong\u003e — studied for effects on lipid metabolism, visceral vs subcutaneous adipose tissue distribution, insulin sensitivity, and cardiometabolic risk markers in aging and metabolic disease models\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eGrowth hormone deficiency models\u003c\/strong\u003e — used as a tool compound in comparative research examining GH secretagogue classes (GHRH analogues vs GHSR agonists such as ipamorelin), receptor pathway selectivity, and GH pulse amplitude optimisation\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eDPP-4 resistance \u0026amp; peptide stability\u003c\/strong\u003e — the trans-3-hexenoic acid modification makes tesamorelin a model compound for studying N-terminal peptide engineering strategies aimed at improving proteolytic stability\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eComparative GH secretagogue studies\u003c\/strong\u003e — frequently paired with CJC-1295 (without DAC) to examine GHRH receptor pathway activity, or with ipamorelin for dual-receptor GH synergy studies investigating amplified GH secretion versus individual secretagogue effects\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eNeuroendocrine \u0026amp; ageing research\u003c\/strong\u003e — investigation of age-related GH decline (somatopause), GH pulse attenuation, and restoration of youthful GH secretory profiles in ageing models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eProduct Specifications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 218949-48-5\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSynonyms:\u003c\/strong\u003e TH9507, Egrifta (brand)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eFull Sequence:\u003c\/strong\u003e Trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₂₂₁H₃₆₆N₇₂O₆₇S\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 5,135.86 g\/mol\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAmino Acids:\u003c\/strong\u003e 44 (plus trans-3-hexenoic acid N-terminal modification)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePubChem CID:\u003c\/strong\u003e 16137828\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eQuantity:\u003c\/strong\u003e 10mg per vial\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eVolume:\u003c\/strong\u003e 3ml (pre-mixed)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥99% (HPLC \u0026amp; MS verified)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Pre-mixed solution\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAppearance:\u003c\/strong\u003e Clear to off-white solution\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSolubility:\u003c\/strong\u003e Soluble in sterile\/bacteriostatic water; introduce water slowly against the glass wall due to high molecular weight\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Refrigerate at 2–8°C once mixed. Protect from light at all stages — the N-terminal trans-3-hexenoic acid modification is light-sensitive. Do not freeze reconstituted solution. Avoid repeated freeze-thaw cycles. Lyophilised (unmixed) stable at −20°C for up to 24 months.\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eShelf life (pre-mixed):\u003c\/strong\u003e Use within 28 days. Inspect before each use — discard if discoloured or particulate present.\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eDispatch:\u003c\/strong\u003e Fast UK dispatch. Orders placed before 2pm dispatched same working day.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eConcentration\u003c\/strong\u003e At 10mg in 3ml: \u003cstrong\u003econcentration = 3.33mg\/ml (3,333mcg\/ml)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCOA Available:\u003c\/strong\u003e Every batch independently third-party tested. Certificate of Analysis available on our Lab Reports page before ordering.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cem\u003eAll products sold by Ultra Peptides are strictly for laboratory and in-vitro research purposes only. Not intended for human or veterinary use outside of licensed clinical contexts. Not approved by the MHRA for general medical or therapeutic application in the UK. By purchasing this product you confirm your intended use is for legitimate scientific research conducted in a controlled laboratory setting.\u003c\/em\u003e\u003c\/p\u003e","brand":"Ultra Peptides","offers":[{"title":"Default Title","offer_id":47496684634306,"sku":null,"price":49.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0742\/4481\/7090\/files\/Tesamorelin---10mg--3ml.png?v=1776891193","url":"https:\/\/ultrapeptides.co.uk\/products\/tesamorelin-10mg-3ml-research-peptide-uk","provider":"Ultra Peptides","version":"1.0","type":"link"}